Diagnostic Center | August 26, 2024
Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Majority of organizations are looking to increase investments in public and hybrid cloud
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
This project is supported by the Irish Government through IDA Ireland
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Report highlights significant improvements in adolescent well-being in India
Subscribe To Our Newsletter & Stay Updated
